首页> 美国卫生研究院文献>Virology Journal >A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection
【2h】

A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection

机译:包含E6和E7血清反应性表位的新型基于HPV 16 L1的嵌合病毒样颗粒可高度特异性地检测CIN 1和HPV-16感染患者的抗体

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundThe presence of IgG antibodies to HPV-16 L1-virus like particles (VLPs) in serum has been reported as a result of persistent exposure to the virus and as a marker of disease progression. However, detection of VLP-specific antibodies in sera does not always indicate a malignant lesion as positive results may also be due to a nonmalignant viral infection. Furthermore, malignant lesions are associated with an increased antibody titer for E6 and E7 proteins. The aim of this study was to develop an ELISA using a novel chimeric virus-like particle (cVLP) encoding an L1 protein fused with a string of HPV-16 E6 and E7 seroreactive epitopes to its C-terminus to be used for detection of HPV-16 specific antibodies in patients with cervical intraepithelial lesion grade 1 (CIN 1).
机译:背景技术据报道,由于持续暴露于病毒并作为疾病进展的标志,血清中存在针对HPV-16 L1病毒样颗粒(VLP)的IgG抗体。但是,在血清中检测到VLP特异性抗体并不总是表明恶性病变,因为阳性结果也可能是由于非恶性病毒感染所致。此外,恶性病变与E6和E7蛋白的抗体效价升高有关。这项研究的目的是开发一种使用新型嵌合病毒样颗粒(cVLP)的ELISA,该颗粒编码L1蛋白,并在其C端融合了一系列HPV-16 E6和E7血清反应性抗原决定簇,用于检测HPV宫颈上皮内病变1级(CIN 1)患者的-16种特异性抗体。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号